title: Combination PARP and HDAC inhibition as a therapeutic strategy targeting liver cancer stem cells?
authors.affiliation: Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne, UK.
authors.forename: Catherine E
authors.initials: CE
authors.lastname: Willoughby
authors.affiliation: Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK. H.L.Reeves@newcastle.ac.uk.
authors.forename: Helen L
authors.initials: HL
authors.lastname: Reeves
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D056572:Histone Deacetylase Inhibitors / Q000008:administration & dosage; D006801:Humans; D008113:Liver Neoplasms / Q000188:drug therapy* / Q000201:enzymology / Q000473:pathology*; D014411:Neoplastic Stem Cells / Q000187:drug effects* / Q000201:enzymology*; D000067856:Poly(ADP-ribose) Polymerase Inhibitors / Q000008:administration & dosage
chemical_list: D056572:Histone Deacetylase Inhibitors; D000067856:Poly(ADP-ribose) Polymerase Inhibitors